Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
106 hedge funds and large institutions have $69.3M invested in Sanofi Contingent Value Rights in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 8 closing their positions.
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
3% more funds holding
Funds holding: 103 → 106 (+3)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less capital invested
Capital invested by funds: $73.1M → $69.3M (-$3.75M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BHMP
Bardin Hill Management Partners
New York
|
+$430K |
| 2 |
SCM
Stonehill Capital Management
New York
|
+$153K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$97.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$67.2K |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$53.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Korea Investment Corp
Seoul,
South Korea
|
-$23K |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
-$11.3K |
| 3 |
US Bancorp
Minneapolis,
Minnesota
|
-$4.67K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.65K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.2K |
GCVRZ Hedge Fund Activity: Q1 2019 in Review
106 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2019, worth a combined $69.3M — down 5.1% from $73.1M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new GCVRZ positions and 8 closed out — a net gain of 5 holders — while 16 added to existing stakes and 15 trimmed.
The largest buyer was Bardin Hill Management Partners, opening a new position worth an estimated $430K. The largest seller was Korea Investment Corp, exiting entirely with an estimated $23K sold.
- 106 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2019, up from 103 in Q4 2018.
- Funds reported $69.3M of Sanofi Contingent Value Rights stock for Q1 2019, down 5.1% quarter-over-quarter.
- 13 funds opened new Sanofi Contingent Value Rights positions in Q1 2019 and 8 closed out, a net change of +5 holders.
- The largest Sanofi Contingent Value Rights buyer in Q1 2019 was Bardin Hill Management Partners, an estimated $430K added.
- The largest Sanofi Contingent Value Rights seller in Q1 2019 was Korea Investment Corp, an estimated $23K sold.
Based on aggregated 13F filings for Q1 2019.